Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ann Childress

Child & Adolescent Psychiatry Las Vegas, NV Medical Doctor

NPI 1457303828 CMS profile 19942

4000 E. Charleston Blvd., B-130, Las Vegas, NV 89104

Open in the dashboard

General payments

$1,378,569

981 records reported · program years 2019–2025

Research payments

$106,214

Paid to them · 66 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,223,379 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Ann Childress of Las Vegas, NV is reported in the CMS Open Payments database as having received $1,378,569 across 981 general payments and $106,214 in research payments paid to them. Separately, studies naming them as principal investigator received $2,223,379 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $635,208 140
2024 General $162,918 175
2023 General $138,515 126
2023 Research $2,436 10
2022 General $128,728 110
2021 General $115,888 115
2021 Research $79,097 12
2020 General $31,074 35
2020 Research $2,269 10
2019 General $166,239 280
2019 Research $22,411 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ann Childress
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Ann Childress were reported at $635,208. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Ann Childress Child & Adolescent Psychiatry median Middle half National median
2019 $166,239 $129 $42–$419 $163
2020 $31,074 $81 $28–$226 $114
2021 $115,888 $115 $31–$326 $132
2022 $128,728 $124 $40–$382 $149
2023 $138,515 $130 $45–$420 $160
2024 $162,918 $141 $42–$490 $164
2025 $635,208 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tris Pharma Inc $528,919 68 payments
  2. Supernus Pharmaceuticals, Inc. $416,763 442 payments
  3. Ironshore Pharmaceuticals Inc. $147,795 209 payments
  4. Corium, Inc. $93,822 79 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $72,552 66 payments
  6. Collegium Pharmaceutical, Inc. $44,316 39 payments
  7. Adlon Therapeutics L.P. $17,784 10 payments
  8. Vertical Pharmaceuticals, LLC $15,571 3 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $14,852 21 payments
  10. Noven Pharmaceuticals, Inc. $9,753 6 payments
  11. Other $16,441 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $482,400 1 payment
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $462,842 192 payments
  3. Consulting Fee $164,290 77 payments
  4. Honoraria $150,755 52 payments
  5. Travel and Lodging $79,196 368 payments
  6. Food and Beverage $19,668 281 payments
  7. Compensation for serving as faculty or as a speaker for a medical education program $12,282 8 payments
  8. Education $7,135 2 payments
Products named General payments · program years 2019–2025
  1. Onyda XR $482,400 1 payment
  2. Qelbree Viloxazine Hydrochloride $188,062 213 payments
  3. QELBREE Psychology $143,079 150 payments
  4. Jornay PM 20mg capsules (Bottle of 100) $112,780 200 payments
  5. Azstarys $93,822 79 payments
  6. Jornay PM Adhd $44,316 39 payments
  7. JORNAY PM Central Nervous Stimulant ADHD $34,920 8 payments
  8. Dyanavel XR $33,864 52 payments
  9. ADHANSIA XR $17,252 9 payments
  10. Relexxii $15,571 3 payments
  11. Other $82,720 137 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Purdue Pharma L.P. $79,097 12 payments
  2. Arbor Pharmaceuticals, Inc. $18,072 5 payments
  3. Supernus Pharmaceuticals, Inc. $3,186 17 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,590 8 payments
  5. ACADIA Pharmaceuticals Inc $1,386 9 payments
  6. Neos Therapeutics, LP $1,374 6 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $907 8 payments
  8. Allergan Inc. $600 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

12

Median for Neuropsychiatry: 88

Drug cost

$40

Median for Neuropsychiatry: $2,689

Branded share of claims

0%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zolpidem Tartrate Generic 12 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $99,543
$99,543 — —
Azstarys
  • Corium, Inc. $18,827
$18,827 — —
Xelstrym
  • Noven Pharmaceuticals, Inc. $5,505
$5,505 — —
Relexxii
  • Vertical Pharmaceuticals, LLC $5,400
$5,400 — —
Dyanavel XR
  • Tris Pharma Inc $1,945
$1,945 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

1,047 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record